Trial Profile
A study to assess the anti-albuminuric effects and variability in response to dapagliflozin in subjects with type 2 diabetes
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Aug 2021
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms IMPROVE
- 01 Aug 2021 Results of post-hoc exploratory analysis of three randomized studies (DELIGHT (NCT02547935), IMPROVE (Netherlands Trial Register NTR4439) and DIAMOND (NCT03190694)) published in the Diabetes, Obesity and Metabolism.
- 01 Jan 2018 Status changed from recruiting to completed, according to results published in the Diabetes, Obesity and Metabolism.
- 07 Jun 2014 New source identified and integrated (European Clinical Trials Database record: EudraCT2014-000157-37)